Quercetin (Q), a flavonoid compound, which is obtained in variety of fruits, seeds, and vegetables, has been reported to possess many pharmacological properties including cancer-preventive and anticancer effects. However, studies on the anticancer effects and underlying mechanisms of Q in human hepatocellular carcinoma (HCC) are still limited. The present study is conducted to investigate the anticancer efficacy and adjuvant chemotherapy action of Q in HCC. HCC cell lines HepG2 and SMCC-7721 were treated with different concentrations of Q. The antiproliferative effects of Q were measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), and the apoptosis and cell cycle dynamics were assessed by flow cytometry; the expression of apoptosis-associated proteins were evaluated by Western blot and immunohistochemistry staining; the tumor growth in vivo was evaluated in a xenograft mouse model. Our results showed that Q effectively inhibited human HCC cell proliferation and induced apoptosis by upregulating the expression of Bad and Bax and downregulating the expression of Bcl-2 and Survivin in vitro. Furthermore, Q obviously inhibited the tumor growth and enhanced the 5-fluorouracil (5-FU) therapeutic efficacy in vitro and in vivo. Taken together, our findings highlight that Q effectively inhibited the growth of tumor and enhanced the sensitivity to thermotherapy, indicating Q is a potential treatment option for HCC.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13277-015-4501-0DOI Listing

Publication Analysis

Top Keywords

5-fu therapeutic
8
therapeutic efficacy
8
hepatocellular carcinoma
8
anticancer effects
8
hcc cell
8
tumor growth
8
effectively inhibited
8
hcc
5
quercetin induces
4
induces apoptosis
4

Similar Publications

Background: Numerous studies have explored the role of vitamin D in various cancers; however, its impact on advanced biliary tract cancers (BTC) within a prospective cohort remains to be investigated. This preplanned subgroup analysis of the NIFTY trial evaluated the prognostic implications of serum vitamin D levels in patients with advanced BTC undergoing second-line chemotherapy.

Methods: From the 174 patients in the NIFTY trial, a total of 173 patients (99.

View Article and Find Full Text PDF
Article Synopsis
  • Chemotherapy significantly improves prognosis for colorectal cancer patients, but resistance to drugs like 5-Fluorouracil (5-FU) is a growing problem.
  • Research identified that nucleotide metabolism may play a key role in both cancer progression and drug resistance, leading to the development of a risk score model to predict patient outcomes.
  • The study found that the gene NDUFA4L2 enhances colon cancer cell growth and movement, contributing to resistance against 5-FU, highlighting its potential as a target for improving treatment strategies.
View Article and Find Full Text PDF

We compared the cost-effectiveness of gemcitabine plus nab-paclitaxel (GnP) and modified FOLFIRINOX (mFFX)-standard first-line treatments for metastatic pancreatic cancer in Japan. This retrospective cohort study included patients with metastatic pancreatic cancer treated at the National Cancer Center Hospital East in Japan between December 2013 and February 2017. A partitioned survival model, featuring five mutually exclusive health states, was developed.

View Article and Find Full Text PDF

DPYD genotype should be extended to rare variants: report on two cases of phenotype / genotype discrepancy.

Cancer Chemother Pharmacol

January 2025

Service de Génomique des Tumeurs et Pharmacologie, Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris, Paris, France.

The enzyme dihydropyrimidine dehydrogenase (DPD) is the primary catabolic pathway of fluoropyrimidines including 5 fluorouracil (5FU) and capecitabine. Cases of lethal toxicity have been reported in cancer patients with complete DPD deficiency receiving standard dose of 5FU or capecitabine. DPD is encoded by the pharmacogene DPYD in which more than 200 variants have been identified.

View Article and Find Full Text PDF
Article Synopsis
  • The incidence and mortality rates of cutaneous squamous cell carcinoma (cSCC) are increasing, highlighting the urgent need for better prevention methods.
  • Topical treatments like calcipotriol and 5-fluorouracil (5-FU) can eliminate actinic keratosis (AK) lesions, but their exact mechanisms weren't clear until recent research.
  • A study shows that type 2 immunity, specifically the interaction between thymic stromal lymphopoietin (TSLP) and Th2 cells, is crucial for eliminating premalignant cells and could be targeted for cSCC prevention.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!